Annabel Samimy
Stock Analyst at Stifel
(4.45)
# 275
Out of 5,169 analysts
57
Total ratings
46.3%
Success rate
40.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Buy | $40 → $50 | $26.92 | +85.74% | 3 | Mar 5, 2026 | |
| EOLS Evolus | Maintains: Buy | $20 → $17 | $4.91 | +246.23% | 2 | Jan 13, 2026 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $15 → $18 | $11.19 | +60.86% | 1 | Dec 19, 2025 | |
| SUPN Supernus Pharmaceuticals | Maintains: Hold | $50 → $55 | $50.82 | +8.23% | 8 | Dec 19, 2025 | |
| RGNX REGENXBIO | Maintains: Buy | $40 → $45 | $8.64 | +420.83% | 3 | Dec 19, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $45 → $52 | $25.02 | +107.83% | 2 | Dec 19, 2025 | |
| MBX MBX Biosciences | Maintains: Buy | $45 → $50 | $29.74 | +68.12% | 2 | Dec 19, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $55 → $48 | $18.82 | +155.05% | 4 | Dec 19, 2025 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $220 → $230 | $210.99 | +9.01% | 2 | Dec 10, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $50 → $90 | $56.15 | +60.28% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $87 → $145 | $120.80 | +20.03% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $3.53 | +409.92% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $17 | $6.16 | +175.97% | 4 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $8.89 | +102.47% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $10.85 | +121.20% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $35.53 | +125.16% | 6 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $225 → $230 | $181.37 | +26.81% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.31 | +1,732.06% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $2.23 | +33,532.29% | 3 | Apr 16, 2020 |
Oculis Holding AG
Mar 5, 2026
Maintains: Buy
Price Target: $40 → $50
Current: $26.92
Upside: +85.74%
Evolus
Jan 13, 2026
Maintains: Buy
Price Target: $20 → $17
Current: $4.91
Upside: +246.23%
Trevi Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $15 → $18
Current: $11.19
Upside: +60.86%
Supernus Pharmaceuticals
Dec 19, 2025
Maintains: Hold
Price Target: $50 → $55
Current: $50.82
Upside: +8.23%
REGENXBIO
Dec 19, 2025
Maintains: Buy
Price Target: $40 → $45
Current: $8.64
Upside: +420.83%
Mineralys Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $52
Current: $25.02
Upside: +107.83%
MBX Biosciences
Dec 19, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $29.74
Upside: +68.12%
Apellis Pharmaceuticals
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $18.82
Upside: +155.05%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $210.99
Upside: +9.01%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $50 → $90
Current: $56.15
Upside: +60.28%
Nov 24, 2025
Maintains: Buy
Price Target: $87 → $145
Current: $120.80
Upside: +20.03%
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $3.53
Upside: +409.92%
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $6.16
Upside: +175.97%
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $8.89
Upside: +102.47%
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $10.85
Upside: +121.20%
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $35.53
Upside: +125.16%
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $181.37
Upside: +26.81%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.31
Upside: +1,732.06%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $2.23
Upside: +33,532.29%